UPDATE: Goldman Sachs Upgrades Hill-Rom Holdings to Buy Hospita Bed Market Rebound
Goldman Sachs raised its rating on Hill-Rom Holdings (NYSE: HRC) from Neutral to Buy and increased its price target from $30 to $39.
Goldman Sachs commented, "Our Buy rating is based on the following: (1) a stabilization and potential improvement in the company's core bed business, notably in the US, which should help drive a positive inflection point on the top line in the near to intermediate term; (2) International expansion helping to support longer term results; and (3) an improved outlook on the company's M&A strategy."
Hill-Rom Holdings closed at $28.07 on Monday.
Latest Ratings for HRC
|Dec 2014||Goldman Sachs||Upgrades||Buy||Conviction Buy|
|Nov 2014||Bank of America||Maintains||Underperform|
|Apr 2014||Northcoast Research||Downgrades||Buy||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.